Kursinformationen (Nasdaq)
- Tagestief / Hoch-
- 52W-Tief / Hoch5,222-24,800
- Jahrestief / Hoch8,978-24,196
- Volumen Intraday
Wichtigste Eigenschaften
Werbung
Schnellsuche von
Termine von Acorda Therapeutics Inc.
Keine aktuellen Termine
Beschreibung
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.
Pivot-Points (Nasdaq)
NameWert
- Pivot-HBOP - R313,357 $
- Pivot-Resist - R212,679 $
- Pivot-High - R111,359 $
- Pivotpunkt10,681 $
- Pivot-Low - S19,361 $
- Pivot-Support - S28,683 $
- Pivot-LBOP - S37,363 $
Passender Service zu Acorda Therapeutics Inc.
Webinar zu Acorda Therapeutics Inc.
Erhalte jetzt Zugriff auf konkrete Trading- und Investmentideen Deiner stock3-Experten mit stock3 Trademate.
Acorda Therapeutics Inc. Kurse
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
VK | ||||||
VK |
Wichtige Bewertungskennzahlen
Keine Kennzahlen vorhanden
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
1,79 %
Intraday
-16,50 %
1 Woche
3,23 %
1 Monat
-33,35 %
Seit Jahresbeginn
65,11 %
1 Jahr
-88,75 %
3 Jahre
-99,69 %
5 Jahre
-99,75 %
10 Jahre
Peer Group
Merck KGaA 74,26 Mrd. €
Zoetis Inc. 79,08 Mrd. $
Haleon PLC 35,45 Mrd. €
Vifor Pharma AG 10,78 Mrd. Fr
Viatris Inc. Registered Shares o.N. 11,19 Mrd. $
Ipsen S.A. 9,24 Mrd. €
Neurocrine Biosciences Inc. 9,16 Mrd. $
Catalent Inc. 6,81 Mrd. $
Intra-Cellular Therapies Inc. 6,06 Mrd. $
Lantheus Holdings Inc. 5,99 Mrd. $
